​

RenovoRx (RNXT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

RenovoRx Revenue Highlights

Latest Revenue (Y)

$43.00K

Latest Revenue (Q)

$197.00K

Main Segment (Y)

Other Operating Segment

RenovoRx Revenue by Period

RenovoRx Revenue by Year

DateRevenueChange
2024-12-31$43.00K100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

RenovoRx generated $43.00K in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

RenovoRx Revenue by Quarter

DateRevenueChange
2025-03-31$197.00K358.14%
2024-12-31$43.00K100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31-100.00%
2023-12-31-100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

RenovoRx generated $197.00K in revenue during Q1 2025, up 358.14% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

RenovoRx Revenue Breakdown

RenovoRx Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Other Operating Segment$43.00K

RenovoRx's latest annual revenue breakdown by segment (product or service), as of Dec 24: Other Operating Segment (100.00%).

Quarterly Revenue by Product

Product/ServiceMar 25
Other Operating Segment$197.00K

RenovoRx's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Other Operating Segment (100.00%).

RenovoRx Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
LGVNLongeveron$2.39M$603.00K
SABSSAB Biotherapeutics$2.24M$114.70K
NTRBNutriband$2.14M$642.38K
RNXTRenovoRx$43.00K$197.00K
VRAXVirax Biolabs Group$8.56K$76.50K
IKNAIkena Oncology--
ANEBAnebulo Pharmaceuticals--
ADILAdial Pharmaceuticals--
QNRXQuoin Pharmaceuticals--
TPSTTempest Therapeutics-$486.00K
MNPRMonopar Therapeutics--
ELDNEledon Pharmaceuticals-$192.00K
KTTAPasithea Therapeutics--

RNXT Revenue FAQ

What is RenovoRx’s yearly revenue?

RenovoRx's yearly revenue for 2024 was $43K, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. RNXT's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is RenovoRx’s quarterly revenue?

RenovoRx's quarterly revenue for Q1 2025 was $197K, a 358.14% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $43K, a 100.00% increase from the previous quarter (Q3 2024), and a 0% increase year-over-year (Q4 2023). RNXT's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023).

What is RenovoRx’s revenue growth rate?

RenovoRx's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are RenovoRx’s revenue streams?

RenovoRx's revenue streams in c 24 are Other Operating Segment

What is RenovoRx’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of RenovoRx was Other Operating Segment. This segment made a revenue of $43K, representing 100.00% of the company's total revenue.